Compare Stocks

→ What is the 72-Hour Profit Surge? (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERC Cerecor	$14.98 +5.5%	$2.60	$1.98 ▼ $4.50	$1.44B	1.44	1.27 million shs	160,992 shs
KLDO Kaleido Biosciences		$0.00	$0.00 ▼ $0.03	$6.39M	-0.06	4,097 shs	494 shs
TLC Taiwan Liposome	$7.00	$7.10	$4.07 ▼ $7.70	$294.54M	0.99	133,095 shs	12,421 shs
VNRX VolitionRx	$0.85 -4.5%	$0.85	$0.55 ▼ $2.10	$69.76M	1.35	220,036 shs	1,255 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERC Cerecor	+15.23%	+24.73%	+223.95%	+236.63%	+404.38%
KLDO Kaleido Biosciences	0.00%	0.00%	0.00%	0.00%	-50.00%
TLC Taiwan Liposome	0.00%	0.00%	0.00%	0.00%	0.00%
VNRX VolitionRx	+11.27%	+44.22%	+18.72%	-16.81%	+89,014,900.00%

Thousands of investors use this no cost solution | Do you? (Ad)

In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CERC Cerecor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLC Taiwan Liposome	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERC Cerecor	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A
TLC Taiwan Liposome	N/A	N/A	N/A	N/A
VNRX VolitionRx	3.00	Buy	$2.50	194.12% Upside

Current Analyst Ratings

Latest KLDO, CERC, VNRX, TLC, and BVXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/27/2024	VNRX VolitionRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.50

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERC Cerecor	$6.70M	214.66	N/A	N/A	$0.22 per share	68.09
KLDO Kaleido Biosciences	$1.10M	0.00	N/A	N/A	N/A	NaN
TLC Taiwan Liposome	$3.63M	81.14	N/A	N/A	$0.83 per share	8.43
VNRX VolitionRx	$770K	90.60	N/A	N/A	($0.11) per share	-7.73

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERC Cerecor	-$63.50M	-$0.57	N/A	N/A	N/A	-1,194.82%	-261.82%	-133.96%	N/A
KLDO Kaleido Biosciences	N/A	-$2.24	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLC Taiwan Liposome	-$35.02M	-$0.88	N/A	N/A	N/A	-299.27%	-120.45%	-55.11%	N/A
VNRX VolitionRx	-$35.32M	-$0.51	N/A	∞	N/A	-4,557.29%	N/A	-154.24%	5/8/2024 (Estimated)

Latest KLDO, CERC, VNRX, TLC, and BVXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/25/2024	N/A	VNRX VolitionRx	N/A	-$0.11	-$0.11	-$0.11	$0.50 million	$0.24 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERC Cerecor	N/A	N/A	N/A	N/A	N/A
KLDO Kaleido Biosciences	N/A	N/A	N/A	N/A	N/A
TLC Taiwan Liposome	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERC Cerecor	0.79	2.19	2.18
KLDO Kaleido Biosciences	N/A	N/A	N/A
TLC Taiwan Liposome	0.67	3.01	3.01
VNRX VolitionRx	N/A	0.69	0.69

Ownership

Institutional Ownership

Company	Institutional Ownership
CERC Cerecor	62.84%
KLDO Kaleido Biosciences	81.56%
TLC Taiwan Liposome	0.22%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
CERC Cerecor	45.70%
KLDO Kaleido Biosciences	9.00%
TLC Taiwan Liposome	N/A
VNRX VolitionRx	15.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CERC Cerecor	31	96.01 million	N/A	Not Optionable
KLDO Kaleido Biosciences	76	42.62 million	38.79 million	Not Optionable
TLC Taiwan Liposome	2,020	42.08 million	N/A	Not Optionable
VNRX VolitionRx	110	82.07 million	69.43 million	Optionable

KLDO, CERC, VNRX, TLC, and BVXP Headlines

Source	Headline
	VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com americanbankingnews.com - April 26 at 2:18 AM
	VolitionRx (NYSE:VNRX) Now Covered by StockNews.com americanbankingnews.com - April 18 at 2:24 AM
	Research Analysts Set Expectations for VolitionRx Limited's FY2024 Earnings (NYSE:VNRX) marketbeat.com - April 10 at 8:28 AM
	VolitionRx Limited Forecasted to Post Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX) marketbeat.com - April 9 at 6:09 AM
	VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ... msn.com - April 8 at 3:37 PM
	VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis finance.yahoo.com - April 8 at 3:37 PM
	VolitionRx's (VNRX) Overweight Rating Reiterated at Cantor Fitzgerald marketbeat.com - March 27 at 10:15 AM
	VolitionRx (NYSE:VNRX) Releases Earnings Results marketbeat.com - March 26 at 9:17 AM
	VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023 msn.com - March 25 at 9:15 PM
	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update prnewswire.com - March 25 at 4:10 PM
	Earnings Outlook For VolitionRX benzinga.com - March 22 at 11:30 AM
	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update prnewswire.com - March 21 at 8:30 AM
	VolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical Officer finanznachrichten.de - March 21 at 5:25 AM
	VolitionRx Names Andrew Retter Chief Medical Officer markets.businessinsider.com - March 19 at 11:18 PM
	Volition appoints Dr Andrew Retter as Chief Medical Officer finance.yahoo.com - March 19 at 6:17 PM
	VolitionRX Ltd money.usnews.com - March 19 at 8:16 AM
	VolitionRX Stock (AMEX:VNRX), Short Interest Report benzinga.com - February 22 at 10:12 PM
	VolitionRx stock soars after company discloses $13M in milestone payments msn.com - January 2 at 7:35 PM
	VolitionRx milestone payment 'important step forward,' says EF Hutton realmoney.thestreet.com - January 2 at 7:35 PM
	Analyzing VolitionRX Ltd (VNRX) After Recent Trading Activity knoxdaily.com - January 1 at 7:42 AM
	Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society finance.yahoo.com - November 17 at 1:08 PM
	VolitionRx to host Q3 earnings call on November 15 proactiveinvestors.com - November 8 at 2:08 PM
	VolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s Perspective markets.businessinsider.com - October 28 at 11:59 PM
	A company insider recently bought 5,000 shares of VolitionRX Ltd [VNRX]. Should You Buy? knoxdaily.com - October 20 at 1:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cerecor

NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Kaleido Biosciences

NASDAQ:KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Taiwan Liposome

NASDAQ:TLC

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.

VolitionRx

NYSE:VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial